Compounds > mallotojaponin
Page last updated: 2024-12-07

mallotojaponin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mallotojaponin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122659
CHEMBL ID487405
MeSH IDM0191279

Synonyms (11)

Synonym
86828-07-1
1-[3-[[3-acetyl-2,4,6-trihydroxy-5-(3-methylbut-2-enyl)phenyl]methyl]-2,6-dihydroxy-4-methoxy-5-methyl-phenyl]ethanone
mallotojaponin
3-(3,3-(dimethylallyl)-5-(3-acetyl-2,4-dihydroxy-5-methyl-6-methoxybenzyl)-phloracetophenone)
CHEMBL487405
ethanone, 1-(3-((3-acetyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl)-2,4,6-trihydroxy-5-(3-methyl-2-butenyl)phenyl)-
ccris 7218
3-(3,3-dimethylallyl)-5-(3-acetyl-2,4-dihydroxy-5-methyl-6-methoxybenzyl)phloroacetophenone
DTXSID10235846
c24h28o8
1-[3-[(3-acetyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl]-2,4,6-trihydroxy-5-(3-methyl-2-butenyl)phenyl]ethanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID332829Antitumor activity against mouse solid EAC cells xenografted in ddY mouse assessed as tumor weight at 7 mg/kg, ip qd for 3 to 8 days measured after 10 days
AID332827Toxicity in ddY mouse xenografted with mouse solid Ehrlich carcinoma cells assessed as mortality at 7 mg/kg, ip qd for 3 to 8 days measured after 10 days
AID338780Cytotoxicity against mouse B16 cells
AID400039Cytotoxicity against human KB cells
AID460579Inhibition of HIV reverse transcriptase at 25 ug/mL2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols.
AID400040Cytotoxicity against mouse L5178Y cells
AID338774Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids at 2 ug/ml after 1 hr
AID338779Cytotoxicity against human PC13 cells
AID338782Cytotoxicity against mouse P388 cells
AID332825Cytotoxicity against mouse L5178Y cells
AID338776Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids after 1 hr
AID332831Antitumor activity against mouse solid EAC cells xenografted in ddY mouse at 7 mg/kg, ip qd for 3 to 8 days measured after 10 days relative to control
AID338778Cytotoxicity against human Hep2 cells
AID338781Cytotoxicity against mouse L5178Y cells
AID332826Toxicity in ddY mouse xenografted with mouse solid Ehrlich carcinoma cells assessed as mortality at 20 mg/kg, ip qd for 3 to 8 days measured after 10 days
AID332833Antitumor activity against mouse EAC cells xenografted in ddY mouse assessed as median survival time at 7 mg/kg, ip qd for 2 to 8 days
AID332828Antitumor activity against mouse solid EAC cells xenografted in ddY mouse assessed as tumor weight at 20 mg/kg, ip qd for 3 to 8 days measured after 10 days
AID338772Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids at 50 ug/ml after 1 hr
AID338773Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids at 10 ug/ml after 1 hr
AID332830Antitumor activity against mouse solid EAC cells xenografted in ddY mouse at 20 mg/kg, ip qd for 3 to 8 days measured after 10 days relative to control
AID332824Cytotoxicity against human KB cells
AID332832Antitumor activity against mouse EAC cells xenografted in ddY mouse assessed as median survival time at 20 mg/kg, ip qd for 2 to 8 days
AID338775Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids at 1.5 ug/ml after 1 hr
AID338777Cytotoxicity against human KB cells
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.46 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phloroglucinol
Phloroglucinol: A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.. phloroglucinol : A benzenetriol with hydroxy groups at position 1, 3 and 5.		2.420benzenetriol;
phenolic donor		algal metabolite
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.0510cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.0510azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		02.0510
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.0510
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		01.9710